John A. Stalfort III - 06 Jul 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director
Signature: /s/ Katherine Denby, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 06 Jul 2021
Net transactions value: +$560,000
Form type: 4
Filing time: 08 Jul 2021, 18:17:32 UTC
Previous filing: 02 Jul 2021
Next filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+130,180	+1822%		137,324	06 Jul 2021	Direct	F1
transaction	ABOS	Common Stock	Purchase	$560,000	+35,000	+25%	$16.00	172,324	06 Jul 2021	Direct
transaction	ABOS	Common Stock	Conversion of derivative security		+131,595			131,595	06 Jul 2021	See footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series A-1 Preferred	Conversion of derivative security	$0	-130,180	-100%	$0.000000^*	0	06 Jul 2021	Common Stock	130,180		Direct	F1
transaction	ABOS	Series B Preferred	Conversion of derivative security	$0	-131,595	-100%	$0.000000^*	0	06 Jul 2021	Common Stock	131,595		See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.